In brief, although CRISPR/Cas9 gene editing technology shows great promise for PD-1/PD-L1-related therapies in tumor immunity, it is still in its infancy and requires a more comprehensive and in-depth investigation of its safety and reliability. The gene discussed is CD274; the disease is neoplasm.